Clinical Trial Update: A Study Evaluating the Efficacy and Safety of AG-348 in Regularly Transfused Adult Participants With Pyruvate Kinase Deficiency (PKD) [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating AG-348 in regularly transfused adults with pyruvate kinase deficiency has completed recruitment with results posted in 2021.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anemia Hemolytic
• Pyruvate Kinase Deficiency

Drugs mentioned

• AG-348 (mitapivat)

Snippet

Sponsor: Agios Pharmaceuticals, Inc. | Conditions: Pyruvate Kinase Deficiency, Anemia, Hemolytic | Phase 3 | Status: COMPLETED | Results posted: 2021-12-10